01931 IVD MEDICAL
Trading Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2024) | |||
| Current | 2.40X | Oper Margin | 14.4% |
|---|---|---|---|
| LT Debt/Equity | N/A | Net Margin | 8.2% |
| Total Debt/Equity | 19.7% | Return on Equity | 7.0% |
| Price/Book | 1.38X | Return on Assets | 4.7% |
| (HKD 3.360) | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
| Net Profit (MHKD) | 276.96 | 262.50 | 235.45 | 213.48 | 188.37 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +5.5 | +11.5 | +10.3 | +13.3 | -38.7 |
| Earnings Per Share (HKD) | 0.185 | 0.194 | 0.175 | 0.161 | 0.142 |
| Earnings Per Share Growth (%) | -4.6 | +10.9 | +8.5 | +14.0 | -47.8 |
| Dividend Per Share (HKD) | No dividend | 0.092 | 0.083 | 0.079 | 0.053 |
| P/E* (X) | 18.14 | 17.30 | 19.19 | 20.82 | 23.73 |
| Yield (%) | N/A | 2.73 | 2.47 | 2.36 | 1.57 |
| Dividend Share (%) | N/A | 47.27 | 47.34 | 49.19 | 37.29 |
| Book NAV (HKD) | 2.430 | 2.722 | 2.610 | 2.693 | 2.539 |
| Auditors' Opinion | Unqualified | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2025-07-22 21:40:20
Latest Result
| (RMBMn) | 2024-12 | 2023-12 | Chg* (%) | 2022-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 3,162 | 3,088 | +2.4 | 2,749 |
| Operating Result | 420.559 | 361.847 | +16.2 | 280.994 |
| Associates | -18.829 | -22.659 | -16.9 | 2.795 |
| Profit Before Taxation | 401.777 | 339.329 | +18.4 | 283.789 |
| Taxation | 135.743 | 102.203 | +32.8 | 88.259 |
| Profit /( Loss) After Taxation | 266.034 | 237.126 | +12.2 | 195.53 |
| Minority Interests | 5.614 | -1.037 | -641.4 | -14.469 |
| Net Profit | 260.42 | 238.163 | +9.3 | 209.999 |
| Earnings Per Share () | 0.1852 | 0.1942 | -4.6 | 0.1751 |
| Dividend Per Share () | 0.0000 | 0.0918 | -100.0 | 0.0829 |
| Announcement Date | 2025-04-11 | 2024-03-15 | NA | 2023-03-17 |
* Annualised
Last Update Time: 2025-07-22 21:40:25
